Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Non-Current Liabilities (2016 - 2025)

Kiora Pharmaceuticals' Other Non-Current Liabilities history spans 10 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 29.87% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, down 29.87%, while the annual FY2025 figure was $2.9 million, 29.87% down from the prior year.
  • Other Non-Current Liabilities reached $2.9 million in Q4 2025 per KPRX's latest filing, down from $16.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $18.8 million in Q2 2022 to a low of -$2.8 million in Q2 2021.
  • Average Other Non-Current Liabilities over 5 years is $6.6 million, with a median of $4.5 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 263.5% in 2021, then surged 772.4% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $3.0 million in 2021, then increased by 9.53% to $3.3 million in 2022, then soared by 53.58% to $5.1 million in 2023, then fell by 18.28% to $4.2 million in 2024, then fell by 29.87% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Other Non-Current Liabilities are $2.9 million (Q4 2025), $16.6 million (Q3 2025), and $4.6 million (Q2 2025).